Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00891137 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
A Phase 1 study, sponsored by Cellerant Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00891137 is a Phase 1 study that has completed, run by Cellerant Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT00891137, a Phase 1 study, has completed, sponsored by Cellerant Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic cancer. In this study, the safety and tolerability of CLT-008 administered 24 hours after an umbilical cord blood transplant will be determined by monitoring for adverse reactions, neutrophil and platelet recovery, hematopoietic chimerism, graft-versus-host disease (GVHD), and infections.
Interventions
- BIOLOGICAL human myeloid progenitor cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-04 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00891137
The ClinicalTrials.gov registry entry for NCT00891137 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cellerant Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which human myeloid progenitor cells is the first listed.
NCT00891137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00891137 about?
NCT00891137 is a clinical study titled "Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy". Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic cancer. In this study, the safety and tolerability of CLT-008 administe...
What is the current status of trial NCT00891137?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2009-04. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00891137?
The interventions under investigation include: human myeloid progenitor cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00891137?
This trial is sponsored by Cellerant Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.